Amylyx Pharmaceuticals, Inc. reported no product revenue for the year ended December 31, 2025, a decrease of $87.4 million compared to the $87.4 million reported for the year ended December 31, 2024, due to the voluntary discontinuation of RELYVRIO/ALBRIOZA. The company's operating expenses totaled $153.3 million, a decrease of $248.8 million from $402.1 million in the prior year. This decrease was primarily driven by reduced research and development spending and selling, general, and administrative expenses, partially offset by a decrease in cost of sales. The net loss for 2025 was $144.7 million, or $(1.31) per share, compared to a net loss of $301.7 million, or $(2.74) per share, for 2024.
Research and development expenses decreased to $90.4 million in 2025 from $104.1 million in 2024, primarily due to decreased spending on AMX0035 for ALS and reduced personnel-related costs following a restructuring. This was partially offset by increased expenses related to the Phase 3 LUCIDITY clinical trial for avexitide in post-bariatric hypoglycemia (PBH) and other research and development activities. Selling, general, and administrative expenses also decreased significantly, totaling $62.9 million in 2025 compared to $114.3 million in 2024, mainly due to lower payroll, consulting, and professional service costs, as well as reduced commercial sales and marketing activity following the discontinuation of RELYVRIO/ALBRIOZA.
Strategic developments included the continued advancement of avexitide in PBH, with recruitment completed for the Phase 3 LUCIDITY trial and topline data expected in Q3 2026, and the ongoing Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome, which demonstrated sustained improvement in pancreatic beta cell function and glycemic control. The company also initiated a Phase 1 clinical trial of AMX0114 in ALS and selected AMX0318 as a development candidate for PBH and other rare diseases, with IND-enabling studies underway. Amylyx is also supporting external research on AMX0035 as adjunctive therapy for type 1 diabetes.
Key operational developments included the completion of recruitment for the Phase 3 LUCIDITY trial of avexitide in PBH, with the last eligible patients expected to be randomized and dosed in Q1 2026, and the presentation of initial safety and tolerability data from Cohort 1 of the Phase 1 LUMINA trial of AMX0114 in ALS. As of December 31, 2025, the company had 136 full-time employees. Amylyx anticipates that its existing cash, cash equivalents, and marketable securities of $317.0 million as of December 31, 2025, will be sufficient to fund operations into 2028. The company continues to evaluate and pursue strategic transactions to further its mission of developing novel therapies for communities with high unmet medical needs.
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative and endocrine diseases with high unmet medical needs. Its pipeline includes investigational drugs like avexitide, a GLP-1 receptor antagonist targeting hyperinsulinemic hypoglycemia, and AMX0035, a combination therapy addressing cellular dysfunction in rare neurodegenerative disorders. Amylyx focuses on rigorous clinical development, proprietary technology, and targeting underserved patient populations through regulatory pathways and intellectual property protection.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.